Cargando…
Clinical Significance of CD200 and CD56 Expression in Patients with Acute Myeloid Leukemia
BACKGROUND: Acute myeloid leukemia (AML) escape from immunosurveillance by immunosuppression. CD200 and CD56 expression represented an independent prognostic factor in many hematological malignancies but its importance in AML patients remains to be identified. METHODS: CD200 and CD56 expression were...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437307/ https://www.ncbi.nlm.nih.gov/pubmed/32212802 http://dx.doi.org/10.31557/APJCP.2020.21.3.743 |
_version_ | 1783572609969946624 |
---|---|
author | Aref, Salah Abousamara, Nashwa El-Helaly, Emann Mabed, Mohamed |
author_facet | Aref, Salah Abousamara, Nashwa El-Helaly, Emann Mabed, Mohamed |
author_sort | Aref, Salah |
collection | PubMed |
description | BACKGROUND: Acute myeloid leukemia (AML) escape from immunosurveillance by immunosuppression. CD200 and CD56 expression represented an independent prognostic factor in many hematological malignancies but its importance in AML patients remains to be identified. METHODS: CD200 and CD56 expression were assessed in the bone marrow blasts for Fifty-two (52) newly diagnosed AML by flowcytometry before start of therapy. RESULTS: CD200 (+) expression was reported in 28.8% of patients while 17.3% of patients showed CD56(+) expression. M4 FAB revealed high frequency of both CD200(+) and CD56(+) expression. The overall survival of CD200(+) patients was 19.2% compared to 35.3% in CD200(-) (P= 0.049). On the other hand, CD56(+) patients had the lowest complete remission rate (22.2% vs. 53.4%). In addition, CD56(+) population had significant bad influence on overall survival than those of CD56(- )population (11.1 % vs. 35.5 %, P= 0.047). CONCLUSIONS: CD200 and CD56 positive expression by myeloblasts at diagnosis denote poor prognostic indicator and correlated with poor cytogenetic findings. CD200 could be used as therapeutic target in AML. |
format | Online Article Text |
id | pubmed-7437307 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | West Asia Organization for Cancer Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-74373072020-09-02 Clinical Significance of CD200 and CD56 Expression in Patients with Acute Myeloid Leukemia Aref, Salah Abousamara, Nashwa El-Helaly, Emann Mabed, Mohamed Asian Pac J Cancer Prev Research Article BACKGROUND: Acute myeloid leukemia (AML) escape from immunosurveillance by immunosuppression. CD200 and CD56 expression represented an independent prognostic factor in many hematological malignancies but its importance in AML patients remains to be identified. METHODS: CD200 and CD56 expression were assessed in the bone marrow blasts for Fifty-two (52) newly diagnosed AML by flowcytometry before start of therapy. RESULTS: CD200 (+) expression was reported in 28.8% of patients while 17.3% of patients showed CD56(+) expression. M4 FAB revealed high frequency of both CD200(+) and CD56(+) expression. The overall survival of CD200(+) patients was 19.2% compared to 35.3% in CD200(-) (P= 0.049). On the other hand, CD56(+) patients had the lowest complete remission rate (22.2% vs. 53.4%). In addition, CD56(+) population had significant bad influence on overall survival than those of CD56(- )population (11.1 % vs. 35.5 %, P= 0.047). CONCLUSIONS: CD200 and CD56 positive expression by myeloblasts at diagnosis denote poor prognostic indicator and correlated with poor cytogenetic findings. CD200 could be used as therapeutic target in AML. West Asia Organization for Cancer Prevention 2020-03 /pmc/articles/PMC7437307/ /pubmed/32212802 http://dx.doi.org/10.31557/APJCP.2020.21.3.743 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Aref, Salah Abousamara, Nashwa El-Helaly, Emann Mabed, Mohamed Clinical Significance of CD200 and CD56 Expression in Patients with Acute Myeloid Leukemia |
title | Clinical Significance of CD200 and CD56 Expression in Patients with Acute Myeloid Leukemia |
title_full | Clinical Significance of CD200 and CD56 Expression in Patients with Acute Myeloid Leukemia |
title_fullStr | Clinical Significance of CD200 and CD56 Expression in Patients with Acute Myeloid Leukemia |
title_full_unstemmed | Clinical Significance of CD200 and CD56 Expression in Patients with Acute Myeloid Leukemia |
title_short | Clinical Significance of CD200 and CD56 Expression in Patients with Acute Myeloid Leukemia |
title_sort | clinical significance of cd200 and cd56 expression in patients with acute myeloid leukemia |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437307/ https://www.ncbi.nlm.nih.gov/pubmed/32212802 http://dx.doi.org/10.31557/APJCP.2020.21.3.743 |
work_keys_str_mv | AT arefsalah clinicalsignificanceofcd200andcd56expressioninpatientswithacutemyeloidleukemia AT abousamaranashwa clinicalsignificanceofcd200andcd56expressioninpatientswithacutemyeloidleukemia AT elhelalyemann clinicalsignificanceofcd200andcd56expressioninpatientswithacutemyeloidleukemia AT mabedmohamed clinicalsignificanceofcd200andcd56expressioninpatientswithacutemyeloidleukemia |